Company / Cost of Revenue
Boston Scientific Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.2B
FY2025
5-year range
$3.1B / $6.2B
FY2021-FY2025
Trend
+18.3%
vs FY2024
Sector context
#18 of 113
Health Care
What the data says
Boston Scientific's cost of revenue of $6.2B is higher than 84% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 5 consecutive years, from $2.8B in FY2020 to $6.2B in FY2025.
Based on SEC 10-K filings.
$6.2B in FY2025 with a 5-year CAGR of +17.2%. Top quartile in the Health Care sector.
Increased from $4.3B to $6.2B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +16.3%
- 5-Year CAGR
- +17.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 113This company $6.2B Sector average $11.3B
▼
-44.9% below sector average
Key checks
Key Insights
- Boston Scientific's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +17.2%, indicating consistent growth.
- In FY2025, cost of revenue increased 18.3% year-over-year.
- Ranks #18 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2B | +18.3% |
| FY2024 | $5.3B | +21.0% |
| FY2023 | $4.3B | +9.8% |
| FY2022 | $4.0B | +27.0% |
| FY2021 | $3.1B | +10.8% |
| FY2020 | $2.8B | -9.7% |
| FY2019 | $3.1B | +10.8% |
| FY2018 | $2.8B | +8.5% |
| FY2017 | $2.6B | +7.0% |
| FY2016 | $2.4B | +11.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026